骨髓甲状腺癌:我们目前对最佳治疗方法的理解
Amanda La Greca1, Bryan Haugen1
1Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado, 12801 East 17th Avenue, 7103 Research 1 South, Aurora, CO, USA.
Endocrinology and metabolism clinics of North America
|July 27, 2025
概括
甲状腺髓性癌 (MTC) 是一种罕见的甲状腺癌,具有诊断方面的挑战. 包括RET-激酶抑制剂在内的先进疗法正在改善患者的治疗结果.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 医学诊断 医学诊断 医学诊断
背景情况:
- 髓性甲状腺癌 (MTC) 是一种罕见的内分泌瘤,与差异化甲状腺癌不同.
- 通过标准的超声波成像和细针吸收,MTC诊断可能具有挑战性,需要考虑非典型的甲状腺结节.
- 血清色素和癌胚抗原水平,以及它们的翻倍时间,对于手术指导,监测和预后评估至关重要.
研究的目的:
- 审查甲状腺髓癌的诊断考虑因素.
- 突出特定生物标志物在MTC管理中的作用.
- 讨论MTC当前和新兴的治疗策略.
主要方法:
- 对MTC的诊断方式的文献综述.
- 在MTC中分析血清素和癌胚抗原的效用.
- 系统性治疗选择的概述,包括向药物.
主要成果:
- MTC需要高的怀疑指数在非典型的甲状腺结节.
- 素和癌胚抗原的翻倍时间是有价值的预后指标.
- 在转移过程中重新排列的 (RET) 导向激酶抑制剂在MTC的全身治疗中显示出显著的疗效.
结论:
- MTC需要一个量身定制的诊断和治疗方法.
- 生物标志物监测对于有效的MTC患者管理至关重要.
- 针对性疗法,如RET抑制剂,代表了MTC治疗的重大进展.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy
662
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
662
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


